导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 29.36% | 90/4773 |
| 近一周 | -1.73% | 684/5462 |
| 近一月 | -6.54% | 3559/5421 |
| 近一季 | -11.63% | 3744/5209 |
| 近半年 | 28.18% | 74/4920 |
| 近一年 | 35.01% | 130/4366 |
| 近两年 | 184.74% | 95/2954 |
| 近三年 | 155.68% | 31/2253 |
| 成立以来 | 72.95% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.65% 4171/4961 |
95.48% 122/5312 |
- - |
- - |
| 2025 | 56.90% 299/4813 |
3.30% 1125/3635 |
1.30% 2389/4076 |
57.00% 165/4524 |
-4.50% 3456/4813 |
| 2024 | 24.56% 286/3463 |
-6.10% 2010/2808 |
5.25% 194/3014 |
13.35% 2186/3129 |
11.19% 230/3463 |
| 2023 | 3.74% 264/2656 |
16.37% 200/2280 |
-4.36% 1151/2385 |
-7.95% 1647/2515 |
1.25% 100/2655 |
| 2022 | -35.80% 1732/2207 |
-24.04% 1753/1919 |
1.03% 1509/2016 |
-18.08% 1679/2113 |
2.13% 1032/2208 |
| 2021 | 17.25% 239/1822 |
-6.69% 1028/1255 |
21.96% 128/1330 |
-6.25% 908/1466 |
9.90% 108/1822 |
| 2020 | 41.42% 291/1250 |
-4.33% 356/1028 |
32.03% 35/1067 |
6.57% 828/1164 |
5.05% 812/1184 |
| 2019 | 67.43% 34/1092 |
37.19% 77/754 |
-10.46% 737/804 |
20.84% 8/850 |
12.80% 34/918 |
| 2018 | -39.82% 614/834 |
- - |
- - |
- - |
-14.27% 573/691 |
| 2017 | 22.30% 151/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.28% 354/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万中证申万电子行业投资指数(LOF)A VS. 长安沪深300非周期A(740101) |